Stone X Group Inc. Inhibikase Therapeutics, Inc. Transaction History

Stone X Group Inc.

  • $2.29 Trillion
  • Q3 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Aug 13, 2025
BUY
$0.76 - $5.46 $10,117 - $72,688
13,313 New
13,313 $12.1 Million

Others Institutions Holding IKT

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Inhibikase Therapeutics, Inc.

IKT Quotes by TradingView
  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $38.6M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email